KMT2A and myeloid neoplasm: Homozygous mutations of EZH2 were recognized in myeloid malignancies.42EZH2 mutations result in worse prognosis and lower relapse-free survival in AML patients.43, 44OR-S1 and UNC1999 demonstrate a meaningful decrease in clonogenic potentiality and increase in differentiation of MLL-AF9 as well as MLL-AF10 leukemic cells.45, 46